CareDx Stock (NASDAQ:CDNA)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$23.46

52W Range

$10.96 - $24.13

50D Avg

$20.76

200D Avg

$18.07

Market Cap

$1.22B

Avg Vol (3M)

$717.76K

Beta

2.48

Div Yield

-

CDNA Company Profile


CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

644

IPO Date

Jul 17, 2014

Website

CDNA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 20
Product$48.38M$40.78M-
Service$274.50M$249.38M-
Digital And Other--$9.28M

Fiscal year ends in Dec 25 | Currency in USD

CDNA Financial Summary


Dec 25Dec 24Dec 23
Revenue$379.81M$333.79M$280.32M
Operating Income$-30.78M$40.77M$-203.36M
Net Income$-21.35M$52.55M$-190.28M
EBITDA$-21.08M$-33.99M$-84.92M
Basic EPS$-0.40$1.00$-3.54
Diluted EPS$-0.40$0.93$-3.54

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26Apr 28, 26 | 12:00 AM
Q4 25Feb 24, 26 | 4:30 PM
Q3 25Nov 04, 25 | 4:30 PM

Peer Comparison


TickerCompany
PSNLPersonalis, Inc.
EMBCEmbecta Corp.
VIRVir Biotechnology, Inc.
DRIODarioHealth Corp.
EVHEvolent Health, Inc.
CSTLCastle Biosciences, Inc.
MYGNMyriad Genetics, Inc.
FLGTFulgent Genetics, Inc.
MRVIMaravai LifeSciences Holdings, Inc.
CRMDCorMedix Inc.